CONFIDENTIAL TREATMENT REQUESTED FOR PORTIONS OF THIS EXHIBIT AMENDMENT NO. 1 TO D-LUCIFERIN SUPPLY AGREEMENTD-Luciferin Supply Agreement • August 15th, 2005 • Xenogen Corp • Measuring & controlling devices, nec
Xenogen Corporation, with a principal place of business at 860 Atlantic Avenue, Alameda, CA 94501 (“Xenogen”) and Biosynth International, Inc., with a principal place of business at 1665 West Quincy Avenue, Suite 155, Naperville, IL 60540 (“Biosynth”), (each a “Party” and collectively, the “Parties”), hereby amend that certain D-Luciferin Supply Agreement, dated December 31, 2001, by and between the Parties hereto (the “Agreement”), effective as of April , 2004 (the “Amendment Date”).
FIRST AMENDMENT TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • August 15th, 2005 • Xenogen Corp • Measuring & controlling devices, nec
This first amendment to that certain Amended and Restated Investors’ Rights Agreement, made as of April 30, 2003 (the “Agreement”), by and among Xenogen Corporation, a Delaware corporation (the “Company”) and the individuals and entities listed on Exhibit A attached thereto (the “Investors”), is made as of August 2, 2005.
